Entomics Competitors

Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.

Buglife is the only organisation in Europe devoted to the conservation of all invertebrates, and we are actively working to save Britain’s rarest little animals, everything from bees to beetles, worms to woodlice and jumping spiders to jellyfish. There are more than 40,000 invertebrate species in the UK, and many of these are under threat as never before. Invertebrates are vitally important to a healthy planet – humans and other life forms could not survive without them. The food we eat, the fish we catch, the birds we see, the flowers we smell and the hum of life we hear, simply would not exist without bugs. Invertebrates underpin life on earth and without them the world’s ecosystems would collapse.

Y-Biologics is Korea’s leading R&D biotech company in the field of antibody drug development. Since establishing Y-Biologics in 2007, our company has focused on the research and development of antibody therapeutics, successfully building antibody platform technologies. Utilizing our excellent and differentiated platform technologies, we are striving to become a leading global antibody drug development company in the field of immuno-oncology & cytokine. Here at Y-Biologics, with our full-cycle antibody development capabilities, we are pursuing full-fledged development of I/O drugs using our bispecific antibody platform. We aim to address unmet medical needs by developing a next-generation immunotherapeutics with higher patient response rates and superior efficacy in comparison to existing I/O drugs. Y-SERVICE Technologys_Antibody Screening, Protein Expression, Cell Line Development, Analysis Service 1. Antibody Screening (Naive Library Screening, Immune Library Screening, Human Nanobody Screening) 2. Antibody Optimization (Antibody Humanization, Affinity Maturation) 3. Transient Recombinant Protein (Antigen & Antibody) Production using HEK293F, ExpiCHO 4. Stable Cell Line Development using Beacon System (ex. SAFC CHOZN) 5. Analysis Services (Hybridoma Sequencing, Biacore 8K/Octet R8, N-Glycan, Endotoxin Test, etc.)